Page 205 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

MUM1 0=negative, (<40%), 1=positive (>40%), 9=not available
GCB/ non GCB, 9=not available
MYC- BA 0=neg 1=pos
BCL2- BA 0=neg 1=pos
BCL6- BA 0=neg 1=pos
ABC/GCB/ undeterminate, 9=not available
WHO 2008
WHO 2017
7
9 9 1 1 1 1 9
9 0 9
1
0
0
0
0
0
0
0
0
0
9
9
9
0
0
9 9 0 9
0 9 0 1 0 9 9 1
9 DLBCL GCB DLBCL GCB DLBCL GCB DLBCL
9 DLBCL GCB DLBCL 9 BCL-U
GCB BCL-U 9 DLBCL
ABC dd DLBCL or BCL-U
HGBCL, DH/TH HGBCL,DH/TH HGBCL,DH/TH HGBCL,DH/TH HGBCL,DH/TH HGBCL,DH/TH dd HGBCL, NOS or HGBCL, DH/ TH HGBCL,DH/TH HGBCL,DH/TH dd DLBCL or HGBCL, NOS
FISH
9 1 0 1 GCB 1 1 0 non-GCB 1 1 0 GCB 1 1 0 non-GCB 1 0 1 9 1 1 0 GCB 1 9 9
GCB 1 1 0 GCB 1 1 0 9 1 0 0
GCB 1 0 0 GCB 1 0 0 GCB 1 1 0 GCB 1 0 0 GCB 1 1 1 GCB 1 0 1 GCB 1 1 1 GCB 1 1 9 GCB 1 1 0 GCB 1 0 0
9 1 0 0 GCB 1 1 0 GCB 1 0 1 GCB 1 1 0 GCB 1 0 0
1
9 1 0 0 GCB 1 0 0 GCB 1 1 0 GCB 1 9 9
9 1 9 9 GCB 1 1 0 GCB 1 1 0
non-GCB 1 0 1 GCB 1 0 0 GCB 1 1 0
9 1 0 0 GCB 1 0 1
GEP Classification
R-CHOP with lenalidomide in MYC+ LBCL
9 BCL-U HGBCL,NOS
poor quality poor quality ABC GCB poor quality 9
DLBCL DLBCL DLBCL DLBCL DLBCL DLBCL
DLBCL HGBCL, DH/TH DLBCL HGBCL,DH/TH HGBCL, DH/TH HGBCL,DH/TH HGBCL,DH/TH HGBCL,DH/TH DLBCL HGBCL,NOS HGBCL,DH/TH HGBCL,DH/TH HGBCL,DH/TH
9 BCL-U GCB DLBCL GCB DLBCL
9 BCL-U GCB DLBCL GCB DLBCL
9 BCL-U
GCB DLBCL DLBCL
synchronous follicular lymphoma
9 DLBCL GCB DLBCL GCB DLBCL
9 DLBCL
9 DLBCL DLBCL 9 DLBCL ABC DLBCL 9 DLBCL GCB DLBCL unclassified DLBCL GCB DLBCL
DLBCL
DLBCL HGBCL,DH/TH
dd DLBCL or HGBCL, DH/TH DLBCL HGBCL, DH/TH HGBCL,DH/TH HGBCL,DH/TH DLBCL HGBCL,DH/TH DLBCL HGBCL,DH/TH
203